EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders

Stefano Fiorucci, Valentina Sepe, Michele Biagioli, Bianca Fiorillo, Pasquale Rapacciuolo, Eleonora Distrutti, Angela Zampella

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2023.115776 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Stefano Fiorucci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy. Electronic address: stefano.fiorucci@unipg.it. Hauptthemen laut MEDLINE: Bile Acids and Salts, Metabolic Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 132 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The farnesoid-x-receptor (FXR) and the G protein bile acid activated receptor (GPBAR)1 are two bile acid activated receptors highly expressed in entero-hepatic, immune, adipose and cardiovascular tissues. FXR and GPBAR1 are clinically validated targets in the treatment of metabolic disorders and FXR agonists are currently trialled in patients with non-alcoholic steato-hepatitis (NASH). Results of these trials, however, have raised concerns over safety and efficacy of selective FXR ligands suggesting that the development of novel agent designed to impact on multiple targets might have utility in the treatment of complex, multigenic, disorders. Harnessing on FXR and GPBAR1 agonists, several novel hybrid molecules have been developed, including dual FXR and GPBAR1 agonists and antagonists, while exploiting the flexibility of FXR agonists toward other nuclear receptors, dual FXR and peroxisome proliferators-activated receptors (PPARs) and liver-X-receptors (LXRs) and Pregnane-X-receptor (PXR) agonists have been reported. In addition, modifications of FXR agonists has led to the discovery of dual FXR agonists and fatty acid binding protein (FABP)1 and Leukotriene B4 hydrolase (LTB4H) inhibitors. The GPBAR1 binding site has also proven flexible to accommodate hybrid molecules functioning as GPBAR1 agonist and cysteinyl leukotriene receptor (CYSLTR)1 antagonists, as well as dual GPBAR1 agonists and retinoid-related orphan receptor (ROR)γt antagonists, dual GPBAR1 agonist and LXR antagonists and dual GPBAR1 agonists endowed with inhibitory activity on dipeptidyl peptidase 4 (DPP4). In this review we have revised the current landscape of FXR and GPBAR1 based hybrid agents focusing on their utility in the treatment of metabolic associated liver disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Acids and SaltsMetabolic DiseasesHumansReceptors, G-Protein-CoupledReceptors, Cytoplasmic and NuclearLiver

Stichwörter der Autor:innen

Bile acidsFXRGPBAR1Intetsinal microbiotaLipid metabolismNon alcoholic steato-hepatitis

Substanzen

Bile Acids and SaltsReceptors, G-Protein-CoupledReceptors, Cytoplasmic and NuclearGPBAR1 protein, human

Autor:innen und Institutionen

  • Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy. Electronic address: stefano.fiorucci@unipg.it.
  • Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.
  • Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Department of Pharmacy, University of Naples "Federico II", Via D. Montesano, 49, Naples I-80131, Italy.
  • Azienda Ospedaliera di Perugia, Perugia, Italy.

Zitieren

APA

Fiorucci, S., Sepe, V., Biagioli, M., Fiorillo, B., Rapacciuolo, P., Distrutti, E., & Zampella, A. (2023). Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115776

Vancouver

Fiorucci S, Sepe V, Biagioli M, Fiorillo B, Rapacciuolo P, Distrutti E, et al. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115776

BibTeX
@article{Fiorucci2023,
  author = {Fiorucci, Stefano and Sepe, Valentina and Biagioli, Michele and Fiorillo, Bianca and Rapacciuolo, Pasquale and Distrutti, Eleonora and Zampella, Angela},
  title = {Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2023.115776}
}
Kostenlos starten →